Techh.info/techtechnology hourly

Immunotherapy

headlines texts
13.11.2018
14:16 FightAging.OrgA Popular Science View of Checkpoint Inhibitor Cancer Immunotherapies

Checkpoint inhibitor therapies are a demonstrably successful approach to cancer immunotherapy. They suppress a mechanism that normally restrains immune cells from attacking other cells. This mechanism is abused by cancers, alongside a variety of other ways in which the immune system can be subverted or quieted. Any advanced tumor tends to have evolved into a state in which it is ignored or even helped by the immune system. Checkpoint inhibitor therapies are an improvement on chemotherapy when it comes to the trade-off between harming the cancer and harming the patient, as well as in the odds of success, but still present risks to patients. Immune checkpoints exist to prevent autoimmunity, and rampant autoimmunity can be just as deadly as any cancer. Our usual defence against […]

Скрыть анонс
09:04 News-Medical.NetStudy finds why obesity both fuels cancer growth and helps immunotherapy kill tumors

A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors.

Скрыть анонс
03:44 Gizmag How can obesity both fuel tumor growth and help new immunotherapy drugs work better?


Two new studies have provided compelling insights into the relationship between obesity and cancer. The research reveals fascinatingly paradoxical effects, suggesting obesity can suppress our immune responses to enhance tumor growth, but also improve the efficacy of a new kind of cancer-killing immunotherapy.
.. Continue Reading How can obesity both fuel tumor growth and help new immunotherapy drugs work better? Category: Medical Tags: Cancer Immunotherapy Obesity

Скрыть анонс
12.11.2018
15:09 KoreaTimes.co.krLG Chem to develop cancer immunotherapy drugs

LG Chem has joined forces with U.S.-based pharmaceutical firm Cue Biopharma to develop cancer immunotherapy drugs, the company said Monday

Скрыть анонс
09.11.2018
13:27 Technology.orgNew immunotherapy technique can specifically target tumor cells, UCI study reports

A new immunotherapy screening prototype developed by University of California, Irvine researchers can quickly create individualized cancer treatments

Скрыть анонс
08.11.2018
22:55 CancerNetwork.comStudy Sheds Light on Risk of Liver Injury in Combined Immunotherapy

The frequency of hepatotoxic immune-related adverse events varied in patients receiving one vs multiple chemotherapy agents.

Скрыть анонс
19:52 ScienceDaily.comCombination chemotherapy and immunotherapy effective in Phase II leukemia study

A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia, according to new findings.

Скрыть анонс
07.11.2018
15:04 News-Medical.NetNew nano-immunotherapy promotes long-term acceptance of transplanted organs

Researchers at the Mount Sinai School of Medicine have developed a new nanotechnology-based immunotherapy that promotes long-term transplant acceptance in an animal model.

Скрыть анонс
11:16 Nanowerk.comNanotechnology-based immunotherapy that promotes organ transplant acceptance

Researchers have developed a novel type of immunotherapy based on innovative nanotechnology that induces long-term organ transplant acceptance in mice. Their study could transform patient care and help to overcome barriers that prevent successful long-term transplant outcomes.

Скрыть анонс
08:28 News-Medical.NetNew immunotherapy screening prototype helps physicians to effectively target tumors

A new immunotherapy screening prototype developed by University of California, Irvine researchers can quickly create individualized cancer treatments that will allow physicians to effectively target tumors without the side effects of standard cancer drugs.

Скрыть анонс
05:21 ScienceDaily.comNanotechnology-based immunotherapy promoting transplant acceptance

Study could transform care for organ transplant recipients.

Скрыть анонс
00:41 ScienceDaily.comNew immunotherapy technique can specifically target tumor cells

A new immunotherapy screening prototype can quickly create individualized cancer treatments that will allow physicians to effectively target tumors without the side effects of standard cancer drugs.

Скрыть анонс
00:01 Phys.orgNew immunotherapy technique can specifically target tumor cells, study reports

A new immunotherapy screening prototype developed by University of California, Irvine researchers can quickly create individualized cancer treatments that will allow physicians to effectively target tumors without the side effects of standard cancer drugs.

Скрыть анонс
06.11.2018
23:59 Medscape.ComOral Immunotherapy Promising for Wheat Allergy

More than half of wheat-allergic children could successfully consume wheat protein at 1 year, but response to oral immunotherapy was lower than for other food allergies, a small study has found.

Скрыть анонс
04:04 ScienceDaily.comFirst-of-its-kind research models immune responses in cellular immunotherapies

Scientists are pursuing a cross-collaborative effort that could potentially change the way cellular immunotherapies such as stem cell transplantation and CAR T-cell therapies are performed.

Скрыть анонс
01.11.2018
17:33 GenEngNews.comConjoined Cells Form a Potent Immunotherapy Combo

Shackled together, stem cells and platelets may help us escape cancer, report UCLA scientists. In the scientists’ new study, the cancer is leukemia, and the defiant ones include a guide, a hematopoietic stem cell (HSC), and a drug carrier, an engineered platelet. The guide brings the duo into bone marrow, and the drug carrier delivers checkpoint inhibition therapy. In experiments with mice that had acute myeloid leukemia, the UCLA team found that their unusual combination therapy halted the disease from developing any further. Of the mice that received the treatment, 87.5 percent were cured by 80 days after the combination cells were injected. Those mice also were all resistant to leukemia cells that were re-injected two months after the 80-day period. Additional details appeared October 29 in the journal Nature Biomedical Engineering , in an article entitled, “ Conjugation of haematopoietic

Скрыть анонс
31.10.2018
21:10 ScienceDaily.comCytokine levels could predict immunotherapy problems

Researchers have identified blood-based biomarkers that may help identify those patients at greatest risk of developing autoimmune side effects from the treatment.

Скрыть анонс
20:39 News-Medical.NetCytokine levels could predict autoimmune reactions to cancer immunotherapy

The development of immunotherapy, which mobilizes the body's own immune system to destroy cancer cells, is one of the greatest advances in cancer treatment, but immunotherapy can cause harm to healthy tissue in some patients.

Скрыть анонс
07:47 News-Medical.NetScientists pinpoint TIM-3 protein as next potential target for immunotherapy treatments

Following the 2018 Nobel Prize for Medicine, global attention is now more than ever turned toward the promise of immunotherapy in oncology. An international team’s work has shed new light on a molecule called TIM-3 that might play a key role in the regulation of the immune response.

Скрыть анонс
07:37 News-Medical.NetScientists find new protein as next potential target for immunotherapy treatments

Scientists and physicians from the Research Institute of the McGill University Health Centre, the Montreal Children's Hospital of the MUHC, and McGill University in collaboration with French teams from AP-HP, Inserm, Université Paris-Descartes and the Imagine Institute at the Necker-Enfants Malades Hospital, have singled out this protein as the next potential target for immunotherapy treatments in patients with cancer and other diseases.

Скрыть анонс
02:43 ScienceDaily.comScientists neutralize reactive nitrogen molecules to enhance cancer immunotherapy

Researchers studying tumors in prostate cancer models found that nitration of an amino acid can inhibit T-cell activation, thwarting the T-cell's ability to kill cancer cells.

Скрыть анонс
02:01 ScienceDaily.comPromising new target for immunotherapy

Researchers have shed new light on a molecule called TIM-3 that might play a key role in the regulation of the immune response.

Скрыть анонс
30.10.2018
10:49 News-Medical.NetScientists find ways to block nitration of amino acids to improve cancer immunotherapy

Immunotherapy -- harnessing T-cells to attack cancer cells in the body -- has given hope to patients who endure round after round of treatment, including chemotherapy, to little effect. For all of its promise, however, immunotherapy still benefits only a minority of patients -- a reality driving research in the field for ways to improve the relatively new approach.

Скрыть анонс
25.10.2018
08:01 Google news Health'Simply cruel': Patient advocates condemn breast cancer immunotherapy hype - HealthNewsReview.org

Скрыть анонс
03:20 Google news Health'Simply cruel': Patient advocates condemn breast cancer immunotherapy hype - HealthNewsReview.org

Скрыть анонс
24.10.2018
21:39 ScienceDaily.comDevice created to deliver immunotherapy without side effects

Scientists have developed a nanodevice to deliver immunotherapy without side effects to treat triple-negative breast cancer. Inserted straight into a tumor, this device makes it possible to deliver a one-time, sustained-release dose that would eliminate the need for patients to undergo several IV treatments over time.

Скрыть анонс
18:11 CancerNetwork.comCan Immunotherapy Improve Outcomes in Triple-Negative Breast Cancer?

Researchers tested whether combining chemotherapy with immunotherapy would offer improved survival for patients with triple-negative breast cancer.

Скрыть анонс
17:45 GenEngNews.comBreast Cancer Immunotherapy Delivered without Side Effects

While cancer immunotherapy is one of the most exciting new research areas due to the potential it holds for treating tumors that have been resistant to traditional therapies, it often still comes with unwanted side effects. Mitigating these negative reactions is a primary goal of clinicians and scientists. One possible mechanism to help diminish side-effects and off-target effects would be to deliver the drug directly to tumors and cancer cells—a strategy that has been notoriously difficult to accomplish. However now, scientists at the Houston Methodist Research Institute have developed a nanodevice to deliver immunotherapy without side effects to treat triple-negative breast cancer. This new direct-to-tumor drug-delivery device makes it possible to deliver a one-time, sustained-release dose that would eliminate the need for patients to undergo several IV treatments over time. This tiny

Скрыть анонс
09:03 News-Medical.NetScientists develop nanodevice to deliver immunotherapy without side effects

Houston Methodist scientists have developed a nanodevice to deliver immunotherapy without side effects to treat triple-negative breast cancer.

Скрыть анонс
23.10.2018
18:55 ScienceDaily.comFirst immunotherapy success for triple-negative breast cancer

New research has shown that by using a combination of immunotherapy and chemotherapy the body's own immune system can be tuned to attack triple-negative breast cancer, extending survival.

Скрыть анонс
11:58 MedicalNewsToday.comMedical News Today: Immunotherapy successful against deadly breast cancer

A new trial confirms that a combination of immunotherapy and chemotherapy boosts survival rates for people with triple-negative breast cancer.

Скрыть анонс
10:30 News-Medical.NetAdvanced breast cancer patients can benefit from immunotherapy-chemotherapy combination

Patients with an aggressive form of advanced breast cancer can benefit from immunotherapy when used in combination with chemotherapy as first-line treatment, according to the results of a large international Phase III clinical trial published today in the New England Journal of Medicine and led by a researcher at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine.

Скрыть анонс
08:16 News-Medical.NetImmunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.

Скрыть анонс
07:09 News-Medical.NetCancer treatment may undergo a paradigm shift to immunotherapy soon

Immunotherapy when used for cancer treatment could extend life longer finds studies. Experts have explained that until now immunotherapy was reserved as a last resort for most patients and treatment usually comprised of chemotherapy and radiation therapy failing which these were tried. In a pair of clinical trials, researchers have found that using immunotherapy as first line treatment can extend lives of these cancer patients.

Скрыть анонс
22.10.2018
20:29 News-Medical.NetImmunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasized, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich.

Скрыть анонс
18:13 Google news HealthSome patients with metastatic triple negative breast cancer live longer with immunotherapy - Medical Xpress

Скрыть анонс
18:03 CancerNetwork.comCan Patients With HIV and a Cancer Diagnosis Safely Receive Immunotherapy?

Researchers tested whether immunotherapy could be safely used in HIV-positive patients with cancer.

Скрыть анонс
17:04 Google news HealthImmunotherapy scores a first win against some breast cancers - Washington Post

Скрыть анонс
15:08 Google news HealthImmunotherapy extends lives of patients with aggressive breast cancer, study says - USA TODAY

Скрыть анонс
13:22 News-Medical.NetImmunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.

Скрыть анонс
13:12 Google news HealthImmunotherapy-chemo combo extends life for women with aggressive form of breast cancer, study finds - FOX43.com

Скрыть анонс
11:50 News-Medical.NetImmunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich.

Скрыть анонс
09:35 News-Medical.NetImmunotherapy increases survival in some patients with metastatic triple negative breast cancer

Immunotherapy improves survival in some patients with metastatic triple negative breast cancer, according to late-breaking results from the IMpassion130 trial reported at the ESMO 2018 Congress in Munich.

Скрыть анонс
09:02 News-Medical.NetImmunotherapy trial offers new hope for people with aggressive breast cancer

There is new hope for people with an aggressive type of breast cancer, as an immunotherapy trial shows for the first time that lives can be extended in people with triple-negative breast cancer.

Скрыть анонс
04:30 Google news HealthImmunotherapy-chemo combo extends life for women with aggressive form of breast cancer, study finds - fox4kc.com

Скрыть анонс
00:51 Google news HealthImmunotherapy-chemo combo extends life for women with aggressive form of breast cancer, study finds - fox2now.com

Скрыть анонс
21.10.2018
14:07 Google news HealthFirst immunotherapy success for triple-negative breast cancer - Medical Xpress

Скрыть анонс
13:33 Google news HealthImmunotherapy scores a first win against some breast cancers - WWLP.com

Скрыть анонс
02:59 Google news HealthImmunotherapy scores a first win against some breast cancers - Washington Post

Скрыть анонс
02:36 Google news HealthNew immunotherapy drug showing promise for aggressive type of breast cancer - CBS News

Скрыть анонс
01:32 Google news HealthImmunotherapy scores a first win against some breast cancers - NBCNews.com

Скрыть анонс
00:33 CNN HealthImmunotherapy-chemo combo extends life for women with aggressive form of breast cancer, study finds

A combination of chemotherapy and immunotherapy added months to the lives of women with triple-negative breast cancer, an aggressive type that attacks women under 50.

Скрыть анонс
00:24 Google news HealthImmunotherapy scores a first win against some breast cancers - NBCNews.com

Скрыть анонс
00:11 Google news HealthImmunotherapy scores a first win against some breast cancers - NBCNews.com

Скрыть анонс
20.10.2018
23:57 Google news HealthImmunotherapy scores a first win against some breast cancers - NBCNews.com

Скрыть анонс
23:11 Google news HealthImmunotherapy scores a first win against some breast cancers - NBCNews.com

Скрыть анонс
22:35 Google news HealthImmunotherapy scores a first win against some breast cancers - Miami Herald

Скрыть анонс
19.10.2018
19:44 News-Medical.NetImmunotherapy medicine found to be effective in treating uveitis

A team of researchers from the UCH CEU's Biomedical Sciences Institute has tested the efficiency of Bevacizumab, medicine used against cancer and in ophtalmology, to treat uveítis, thus stopping the inflammation from spreading.

Скрыть анонс
18.10.2018
14:35 FierceBiotech.comImproving cancer immunotherapy by controlling RNA expression

Scientists have previously managed to control the strength and timing of expression for DNA-based gene therapies, and a group of MIT researchers have now found a way via gene circuit to control the expression of RNA, which they're applying to cancer immunotherapy.

Скрыть анонс
17.10.2018
18:49 CancerNetwork.comIntegrating Immunotherapy Into Colorectal Cancer Care

Until recent studies were reported, immunotherapy was thought to be ineffective for colorectal cancer; this article provides guidance on how to incorporate immunotherapy into this setting.

Скрыть анонс
16.10.2018
20:34 CancerNetwork.comSignificance of MHC-II in Immunotherapy

While previous research has proven the role MHC-I molecules play, a new study in Cell suggests that MHC-II may also play a role in immunotherapy.

Скрыть анонс
15:43 GenEngNews.comImmunotherapeutic Antibody Helps Prevent Neurodegeneration

Scientists from the Gladstone Institutes say they developed an antibody that blocks the inflammatory and oxidative activity of fibrin, which contributes to neurodegeneration in the brain, without compromising the protein's clotting function. To come up with a precise and highly effective antibody, the researchers focused on targeting only a small region of the fibrin protein that is involved in activating the immune system in the brain. This way, they avoided interfering with the part of the protein responsible for clotting. The team’s study (“ Fibrin-targeting Immunotherapy Protects Against Neuroinflammation and Neurodegeneratio n”) appears in Nature Immunology. “Activation of innate immunity and deposition of blood-derived fibrin in the central nervous system (CNS) occur in autoimmune and neurodegenerative diseases, including multiple sclerosis (MS) and Alzheimer’s disease (AD).

Скрыть анонс
08:17 News-Medical.NetResearchers develop fibrin-targeting immunotherapy to protect against neurodegeneration

Normally, the blood protein fibrin does not enter the brain. But in several neurological disorders, the blood-brain barrier--which keeps large molecules in the blood from entering the brain--becomes abnormally permeable, allowing fibrin to leak into the brain and trigger inflammation.

Скрыть анонс
15.10.2018
21:30 ScienceDaily.comNew immunotherapy targeting blood-clotting protein

A team has developed an antibody that blocks the inflammatory and oxidative activity of fibrin, which contributes to neurodegeneration in the brain, without compromising the protein's clotting function.

Скрыть анонс
12.10.2018
09:35 Technology.orgNew immunotherapy offers potential cure for advanced pancreatic cancer

The new cell-based immunotherapy, which has not yet been tested in humans with pancreatic cancer, led to mice

Скрыть анонс
10.10.2018
09:25 Technology.orgImmunotherapy effective against hereditary melanoma

Congenital mutations of the CDKN2A gene are the strongest known risk factors for inherited skin cancer. Individuals with

Скрыть анонс
05:33 ScienceDaily.comImmunotherapy effective against hereditary melanoma

Individuals with an inherited form of skin cancer often have a poor prognosis. The type of immunotherapy that was awarded this year's Nobel Prize in Physiology or Medicine is, however, particularly effective in this patient group, new research shows.

Скрыть анонс
09.10.2018
17:15 GenEngNews.comAffimed Places Cancer Immunotherapy Candidate AFM11 on Clinical Hold after Patient Death

Affimed disclosed that it has placed the two-trial Phase I clinical program for its cancer immunotherapy candidate AFM11 (CD19/CD3-targeting T cell engager) on clinical hold following the death of one patient, and life-threatening events in two others. The death occurred in a Phase I trial ( NCT02106091 ) designed to assess AFM11 in patients with relapsed or refractory CD19 positive B-cell non-Hodgkin lymphoma (NHL). The two life-threatening events both occurred in the program’s other Phase I trial ( NCT02848911 ), designed to determine the maximum tolerated dose in patients with acute lymphoblastic leukemia (ALL), as well as assess safety and tolerability of increasing doses and different infusion times of AFM11 infusion in patients with adult B-precursor ALL. “Affimed will be working closely with the global health authorities, the Safety Monitoring Committees, and the studies' clinical

Скрыть анонс
08.10.2018
10:32 News-Medical.NetImmunotherapy effective for individuals with inherited form of skin cancer

Individuals with an inherited form of skin cancer often have a poor prognosis. The type of immunotherapy that was awarded this year's Nobel Prize in Physiology or Medicine is, however, particularly effective in this patient group, research from Karolinska Institutet in Sweden shows. The study is published in the Journal of Medical Genetics.

Скрыть анонс
07.10.2018
11:31 Google news HealthAllison's Nobel Prize beckons new era of immunotherapy - Houston Chronicle

Скрыть анонс
05.10.2018
15:37 FierceBiotech.comDDF 2018: How do you fix the glut of immunotherapy combo trials?

A bottleneck of immunotherapy clinical trials has put the field’s advancement somewhat on hiatus as researchers and drug companies wait for the next scientific discovery to ignite development, according to panelists at the 2018 FierceBiotech Drug Development Forum.

Скрыть анонс
02:25 ScienceDaily.comSynthetic DNA-encoded checkpoint inhibitor antibodies advance cancer immunotherapy

Scientists demonstrate for the first time that through engineering constructs, they can express DNA-encoded monoclonal antibodies (DMAbs) targeting CTLA-4, an important cancer checkpoint molecule that blocks anti-cancer immunity.

Скрыть анонс
04.10.2018
11:49 MedicalNewsToday.comMedical News Today: Immunotherapy: 'Killer' cells get boost in fight against cancer

Nanoparticles can boost the immune system's natural killer cells in the fight against cancer, making immunotherapy successful in more patients.

Скрыть анонс
03.10.2018
11:14 News-Medical.NetNew way of using natural killer cells makes immunotherapy viable to more patients

Immunotherapy is making headlines for saving the lives of hundreds of cancer patients including former President Jimmy Carter. But many of these therapies, only work for a small portion of people who have a specific molecule called PDL1 in their cancer makeup.

Скрыть анонс
02.10.2018
16:15 Google news Sci/Tech2018 Nobel Prize awarded to cancer immunotherapy pioneers - Big Think (blog)

Скрыть анонс
14:23 Google news Sci/TechJames Allison and Tasuku Honjo win Nobel Prize for landmark cancer immunotherapy discoveries - Los Angeles Times

Скрыть анонс
06:56 Google news HealthJames Allison and Tasuku Honjo win Nobel Prize for landmark cancer immunotherapy discoveries - Los Angeles Times

Скрыть анонс
05:32 Gizmag 2018 Nobel Prize in Medicine awarded to cancer immunotherapy scientists


The 2018 Nobel Prize in Physiology or Medicine has been awarded to James P. Allison and Tasuku Honjo, for their efforts in the development of cancer immunotherapy. In the 1990s, the two Laureates independently studied proteins that act as "brakes" on immune cells, and helped develop ways to lift those brakes to improve the immune system's effectiveness in fighting cancer.
.. Continue Reading 2018 Nobel Prize in Medicine awarded to cancer immunotherapy scientists Category: Medical Tags: Cancer Cells Immunotherapy Nobel prizes Protein The Immune System

Скрыть анонс
05:18 Washington PostNobel Prize in medicine goes to cancer immunotherapy researchers

James P. Allison and Tasuku Honjo, from the United States and Japan, won the prestigious award.

Скрыть анонс
04:41 Arxiv.org StatisticsTOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. (arXiv:1810.00709v1 [stat.ME])

Immunotherapies have revolutionized cancer treatment. Unlike chemotherapies, immune agents often take longer time to show benefit, and the complex and unique mechanism of action of these agents renders the use of multiple endpoints more appropriate in some trials. These new features of immunotherapy make conventional phase II trial designs, which assume a single binary endpoint that is quickly ascertainable, inefficient and dysfunctional. We propose a flexible and efficient time-to-event Bayesian optimal phase II (TOP) design. The TOP design is efficient in that it allows real-time "go/no-go" interim decision making in the presence of late-onset responses by using all available data, and maximizes the statistical power for detecting effective treatments. TOP is flexible in the number of interim looks and capable of handling simple and complicated endpoints under a unified framework. We

Скрыть анонс
01.10.2018
17:43 Google news HealthNobel Prize in medicine goes to cancer immunotherapy researchers - Bangor Daily News

Скрыть анонс
17:32 GenEngNews.comImmunotherapy Pioneers Take 2018 Nobel Prize

This year, the Nobel committee has sought to recognize the enormous potential and meteoric rise in success of immunotherapy as a strategy for treating cancer. By stimulating the inherent ability of our immune system to attack tumor cells this year’s Nobel Laureates have established an entirely new principle for cancer therapy. Specifically, the two recipients of this year’s Nobel Prize in Physiology or Medicine—James Allison, Ph.D., a professor at the University of Texas MD Anderson Cancer Center and Tasuku Honjo, M.D., Ph.D., a professor at Kyoto University—won for their discovery of cancer therapy by inhibition of negative immune regulation. Dr. Allison studied a known protein that functions as a brake on the immune system. He realized the potential of releasing the brake and thereby unleashing our immune cells to attack tumors. He then developed this concept into a brand-new approach for

Скрыть анонс
17:10 GenEngNews.comMerck & Co. Partners with Dragonfly on NK-Based Cancer Immunotherapies

Merck & Co. plans to develop new solid tumor cancer immunotherapies using Dragonfly Therapeutics’ T ri -specific NK cell E ngagement T herapies (TriNKET ™ ) technology platform, through a collaboration that Dragonfly said today could generate for it up to $695 million per program, plus royalties. Neither the number of programs, nor the types of solid tumor malignancies, were disclosed. The collaboration grants Merck the option to license exclusive worldwide intellectual property rights to products developed using Dragonfly’s proprietary TriNKETs, designed to bind to the proteins expressed on both cancer cells and tumor cell-killing NK cells. Through that binding, Dragonfly says, the TriNKETs are intended to stimulate NK cells, making them aware of the cancer and allowing them to both directly kill the cancer cells, and activate T cells and B-Cells to attack the cancer, helping

Скрыть анонс
16:36 Google news HealthScientists behind cancer immunotherapies win Nobel Prize in medicine - New York Post

Скрыть анонс
16:12 Medscape.ComNobel Prize in Medicine Goes to Cancer Immunotherapy Pioneers

Nobel laureates James P. Allison and Tasuku Honjo discovered how the immune system can be harnessed to attack tumor cells, ushering in the era of immune checkpoint inhibitor therapy.

Скрыть анонс
14:14 Reuters.com HealthScientists behind game-changing cancer immunotherapies win Nobel medicine prize

American James Allison and Japanese Tasuku Honjo won the 2018 Nobel Prize for Physiology or Medicine on Monday for game-changing discoveries about how to harness and manipulate the immune system to fight cancer.

Скрыть анонс
14:13 NYT Science2018 Nobel Prize in Medicine Awarded to 2 Cancer Immunotherapy Researchers

James P. Allison and Tasuku Honjo were recognized for a discovery that the body’s immune system can be used to attack cancer cells.

Скрыть анонс
14:12 ReutersScientists behind game-changing cancer immunotherapies win Nobel medicine prize

American James Allison and Japanese Tasuku Honjo won the 2018 Nobel Prize for Physiology or Medicine on Monday for game-changing discoveries about how to harness and manipulate the immune system to fight cancer.

Скрыть анонс
14:12 ReutersScientists behind game-changing cancer immunotherapies win Nobel medicine prize

American James Allison and Japanese Tasuku Honjo won the 2018 Nobel Prize for Physiology or Medicine on Monday for game-changing discoveries about how to harness and manipulate the immune system to fight cancer.

Скрыть анонс
14:03 Google news HealthNobel Prize in medicine goes to cancer immunotherapy researchers - Washington Post

Скрыть анонс
13:31 Google news Health2018 Nobel Prize in Medicine Awarded to 2 Cancer Immunotherapy Researchers - New York Times

Скрыть анонс
13:20 ScienceMag.orgCancer immunotherapy pioneers win medicine Nobel

James Allison and Tasuku Honjo found ways to remove the “brakes” that prevent the immune system from attacking tumor cells.

Скрыть анонс
13:18 NewYork Times2018 Nobel Prize in Medicine Awarded to 2 Cancer Immunotherapy Researchers

James P. Allison and Tasuku Honjo were recognized for a discovery that the body’s immune system can be used to attack cancer cells.

Скрыть анонс
13:17 International Herald Tribune2018 Nobel Prize in Medicine Awarded to 2 Cancer Immunotherapy Researchers

James P. Allison and Tasuku Honjo were recognized for a discovery that the body’s immune system can be used to attack cancer cells.

Скрыть анонс
13:08 NYT Health2018 Nobel Prize in Medicine Awarded to 2 Cancer Immunotherapy Researchers

James P. Allison and Tasuku Honjo were recognized for a discovery that the body’s immune system can be used to attack cancer cells.

Скрыть анонс
10:14 News-Medical.NetInternational conference features cutting-edge research studies on cancer immunotherapy

The Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, to be held in New York, Sept. 30-Oct. 3, will feature cutting-edge research studies from around the world that endeavor to answer urgent questions in the field of cancer immunotherapy to advance progress more rapidly for patients.

Скрыть анонс
05:19 Google news HealthCancer Immunotherapy Conference features latest research on response, resistance, treatment - Science Codex

Скрыть анонс
28.09.2018
17:28 GenEngNews.comRoche Acquires Cancer Immunotherapy Developer Tusk Therapeutics

Roche has acquired Tusk Therapeutics for up to €655 million ($759 million), Tusk said today, in a deal that expands the buyer’s oncology pipeline with two preclinical first-in-class antibodies set to advance into the clinic next year. Based at the Stevenage Bioscience Catalyst in Stevenage, U.K., privately-held Tusk is a developer of immuno-oncology treatments focused on discovering and developing therapeutic antibodies. Tusk is developing a first-in-class anti-CD25 antibody designed to deplete regulatory T-cells (Tregs) and based on the research of Sergio Quezada, Ph.D., Group Leader and Cancer Research UK Senior Research Fellow at University College London’s UCL Cancer Institute, who chairs the company’s Scientific Advisory Board. At the 2018 American Association for Cancer Research (AACR) Annual Meeting, held April 14-18 in Chicago, Tusk presented data in animal models showing that the

Скрыть анонс
16:44 GenEngNews.comDesigner DNA Vaccine for Cancer Immunotherapy

Researchers at The Wistar Institute report that they have used a new structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types of cancer. They say their approach addressed a difficult issue in cancer immunotherapy, specifically how to simultaneously drive antitumor immune responses against multiple tumor antigens in a single, easily delivered formulation and could simplify immunotherapy treatment and may prevent cancer escape from immune pressure as the immune system could attack the cancer at multiple susceptible target points.  The new vaccine, targeting the human cancer-associated MAGE-A family of proteins, was shown to be effective and safe in a melanoma preclinical model, as described in a paper (“ A designer cross-reactive DNA immunotherapeutic vaccine that targets

Скрыть анонс
15:39 GenEngNews.comNew DNA Vaccine Offers Novel Immunotherapeutic Approach Against Cancer

Researchers at The Wistar Institute report that they have used a new structurally designed synthetic DNA vaccine to simultaneously target multiple members of a family of proteins that are specifically overexpressed in several types of cancer. They say their approach addressed a difficult issue in cancer immunotherapy, specifically how to simultaneously drive antitumor immune responses against multiple tumor antigens in a single, easily delivered formulation and could simplify immunotherapy treatment and may prevent cancer escape from immune pressure as the immune system could attack the cancer at multiple susceptible target points.  The new vaccine, targeting the human cancer-associated MAGE-A family of proteins, was shown to be effective and safe in a melanoma preclinical model, as described in a paper (“ A designer cross-reactive DNA immunotherapeutic vaccine that targets

Скрыть анонс
First← Previous12345678910Previous →Last